11Dec/13

Blood donation collectors thrown out of Israeli parliament – Reuters


AFP

Blood donation collectors thrown out of Israeli parliament
Reuters
JERUSALEM (Reuters) – The speaker of Israel’s parliament ordered a blood-collection crew to leave the legislature’s premises on Wednesday after it turned down an offer of a blood donation from an Ethiopian-born lawmaker. Knesset member Pnina 
MDA Accuses Ethiopian MK of Provocation over BloodArutz Sheva
Magen David Adom Won’t Let Ethiopian Jewish Member Of Knesset Donate BloodFailedMessiah.com

all 24 news articles »

11Dec/13

Targeted antibody, immune checkpoint blocker rein in follicular lymphoma – Medical Xpress

Targeted antibody, immune checkpoint blocker rein in follicular lymphoma
Medical Xpress
“The combination of the established antibody drug rituximab with the experimental drug pidilizumab so far also has a remarkably mild side effect profile,” Neelapu said. Of 29 study participants at a median follow-up of 15.4 months, 19 (66 percent) had

and more »

11Dec/13

Researchers Identify a New Way to Predict the Prognosis for Heart Failure Patients – Newswise (press release)


Irish Medical Times

Researchers Identify a New Way to Predict the Prognosis for Heart Failure Patients
Newswise (press release)
Newswise — Johns Hopkins researchers have identified a new way to predict which heart failure patients are likely to see their condition get worse and which ones have a better prognosis. Their study is one of the first to show that energy metabolism
New findings advance the opportunities for a ‘pacemaker in a bottle’Irish Medical Times

all 4 news articles »

11Dec/13

Idelalisib With Rituximab Boosts Survival in Relapsed CLL – Medscape

Idelalisib With Rituximab Boosts Survival in Relapsed CLL
Medscape
In a phase 3 trial, known as Study 116, the investigational agent idelalisib (under development by Gilead), when added to rituximab (Rituxan), improved outcomes in patients with relapsed CLL. “Idelalisib is a targeted, highly selective, orally
Idelalisib plus rituximab extended survival in previously treated CLLHealio
Idelalisib/Rituximab Combo Improves Survival in Late-Stage CLLCancer Network
Gilead’s Pipeline EncouragesYahoo News

all 6 news articles »

11Dec/13

Roche, Prothena Enter Into Worldwide Collaboration to Co-Develop Antibodies … – Benzinga

Roche, Prothena Enter Into Worldwide Collaboration to Co-Develop Antibodies
Benzinga
Roche (OTC: RHHBY) and Prothena Corporation plc (Nasdaq: PRTA), announced today that they have entered into a worldwide collaboration to develop and commercialize antibodies that target alpha-synuclein, including PRX002, Prothena’s monoclonal 
Roche and Prothena to Devlop Antibodies for Parkinson’s DiseasePharmaceutical Processing
Roche and Prothena Enter Into Worldwide Collaboration to Co-Develop and Co MarketWatch
Roche, Prothena ink potential $600 million deal for Parkinson’s diseaseSan Francisco Business Times (blog)
RTT News –Seeking Alpha
all 10 news articles »